Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LISA vs Conventional Curosurf for Preterm Neonates with RDS
NCT02772081Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Poractant alfa in respiratory distress syndrome (RDS), sponsored by Chiesi Farmaceutici S.p.A.. Started May 2021; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT02772081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772081.